Wilson Wolf

Wilson Wolf is a private medical device company that has established itself as a key enabler in the cell and gene therapy (CGT) manufacturing space through its proprietary G-Rex technology. The company's core innovation is a shift from diffusion-based to convection-based nutrient transport in cell culture, allowing for higher cell yields, simpler protocols, and more efficient use of reagents and facility space. By focusing on manufacturing hardware rather than developing its own therapies, Wilson Wolf serves as a critical infrastructure provider to CGT developers globally. Its creation of the ScaleReady consortium with partners like Bio-Techne and Fresenius Kabi further solidifies its position in building an integrated, scalable manufacturing platform.

G-Rex cell culture platform utilizing convection-based nutrient/gas transport for simplified, scalable cell therapy manufacturing.

Wilson Wolf competes with traditional bioreactor companies like Cytiva (WAVE), Sartorius, and Thermo Fisher Scientific, as well as specialized CGT-focused firms like Lonza and Miltenyi Biotec. Its key differentiation is the passive, convection-based G-Rex design, which it positions as simpler, more space-efficient, and less reagent-intensive than perfusion or mixing-based systems.